ASP8302

DRUG2 trials

Sponsors

Astellas Pharma Inc, Astellas Pharma Europe B.V.

Conditions

Healthy SubjectsUnderactive Bladder

Phase 1

ASP8302 Single and Multiple Ascending Oral Dose Study in Non-elderly Healthy Japanese Subjects

CompletedNCT03361540

Astellas Pharma IncHealthy Subjects

Start: 2017-11-14End: 2018-04-30Updated: 2024-10-21

Phase 2

A Study of ASP8302 in Participants With Underactive Bladder

CompletedNCT03702777

Astellas Pharma Europe B.V.Underactive Bladder

Start: 2018-11-20End: 2020-04-28Updated: 2024-11-21